DIAGNOS Announces Amendment to Convertible Debentures

BROSSARD, Quebec, May 20, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the maturity date for $300,000 unsecured convertible debentures (each a “Debenture”) issued as part of a private placement of units initially announced on May 18, 2023. The maturity date, initially set for May 18, 2025, is being extended to May 18, 2026 (the “Amendment”).